Pertussis post-exposure prophylaxis among household contacts: a cost-utility analysis

PloS One
Nisha ThampiBeate Sander

Abstract

Recent pertussis outbreaks have prompted re-examination of post-exposure prophylaxis (PEP) strategies, when immunization is not immediately protective. Chemoprophylaxis is recommended to household contacts; however there are concerns of clinical failure and significant adverse events, especially with erythromycin among infants who have the highest disease burden. Newer macrolides offer fewer side effects at higher drug costs. We sought to determine the cost-effectiveness of PEP strategies from the health care payer perspective. A Markov model was constructed to examine 4 mutually exclusive strategies: erythromycin, azithromycin, clarithromycin, or no intervention, stratified by age group of contacts ("infant", "child", and "adult"). Transition probabilities, costs and quality-adjusted life years (QALYs) were derived from the literature. Chronic neurologic sequelae were modeled over a lifetime, with costs and QALYs discounted at 5%. Associated health outcomes and costs were compared, and incremental cost-effectiveness ratios (ICER) were calculated in 2012 Canadian dollars. Deterministic and probabilistic sensitivity analyses were performed to evaluate the degree of uncertainty in the results. Azithromycin offered the highest QAL...Continue Reading

References

Oct 25, 1979·The New England Journal of Medicine·J P KoplanD W Fraser
Jan 17, 1976·British Medical Journal·C L Miller, W B Fletcher
Feb 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C M MinkD A Blumberg
Mar 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K M FarizoP A Patriarca
Feb 1, 1992·American Journal of Diseases of Children·M A SprauerP A Patriarca
Jul 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J E Hoppe, A Eichhorn
Oct 1, 1995·The Pediatric Infectious Disease Journal·R BortolussiS Halperin
Nov 1, 1995·The Pediatric Infectious Disease Journal·G De SerresB Duval
Jan 1, 1997·Archives of Pediatrics & Adolescent Medicine·M E Pichichero, J Treanor
Jan 10, 1998·Annals of Internal Medicine·J D Cherry
Jan 7, 1997·Journal of Health Economics·A M Garber, C E Phelps
Jan 7, 1997·Journal of Health Economics·D Meltzer
Aug 18, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S A HalperinP Duclos
Jul 7, 2000·The Journal of Infectious Diseases·G De SerresS A Halperin
Dec 15, 2000·Archives of Family Medicine·L H Lee, M E Pichichero
Jul 24, 2001·PharmacoEconomics·M IskedjianA Rosner
Jul 2, 2003·Journal of Public Health Medicine·H DodhiaE Miller
Jul 18, 2003·The Pediatric Infectious Disease Journal·Charles R VitekTrudy V Murphy
Nov 5, 2003·Pediatrics·Alberto E TozziUNKNOWN Progetto Pertosse Working Group
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Masahiro TanakaTrudy V Murphy
Jul 3, 2004·Pediatrics·Joanne M LangleyUNKNOWN Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC)
Dec 4, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Grace M LeeUNKNOWN Massachusetts Pertussis Study Group
Mar 23, 2005·Health and Quality of Life Outcomes·Grace M LeeTracy A Lieu
May 7, 2005·The Pediatric Infectious Disease Journal·J Jaime CaroEvelinda Trindade
May 7, 2005·The Pediatric Infectious Disease Journal·J Jaime CaroJudith A O'Brien
Jun 3, 2005·Pediatrics·Grace M LeeTracy A Lieu
Jun 3, 2005·The Pediatric Infectious Disease Journal·Jeffrey P Davis
Jul 13, 2005·BMC Infectious Diseases·Judith A O'Brien, J Jaime Caro
Jun 13, 2006·Lancet·Natasha S Crowcroft, Richard G Pebody
Nov 14, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·David VickersSyed Shah
Jan 30, 2007·The Pediatric Infectious Disease Journal·Wynne Morrison
Feb 14, 2007·American Journal of Preventive Medicine·Grace M LeeTracy A Lieu
Apr 7, 2007·The Pediatric Infectious Disease Journal·Aaron M WendelboeUNKNOWN Infant Pertussis Study Group
Jul 20, 2007·The Cochrane Database of Systematic Reviews·S AltunaijiJ Massie
Jan 19, 2008·Journal of Health Economics·Robert H Lee
Jun 10, 2008·Vaccine·Grace M LeeCarl Heinz Wirsing von Konig

❮ Previous
Next ❯

Citations

Nov 7, 2015·Paediatric Drugs·Abdulbaset M SalimPaul E Kilgore
Dec 6, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Pere GodoyUNKNOWN Transmission of Pertussis in Households Working Group
Oct 21, 2020·Emerging Infectious Diseases·Josep AlvarezUNKNOWN Transmission of Pertussis in Households Working Group
Oct 21, 2020·CMAJ Open·Bahaa Abu-RayaUNKNOWN for members of the Canadian Immunization Monitoring Program, ACTive (IMPACT)
Apr 1, 2016·Clinical Microbiology Reviews·Paul E KilgoreHeinz-Josef Schmitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.